Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

INSPIRE

Financiado

IN depth SPatiotemporal dissection of autoimmunity induced Inflammation in RhEum...

IN depth SPatiotemporal dissection of autoimmunity induced Inflammation in RhEumatoid arthritis Rheumatoid Arthritis (RA) is a prototypic T cell- and B cell-driven inflammatory autoimmune disease that affects around 1% of the population worldwide and creates a severe burden for patients as well as substantial socioeconomic c... ver más

31/12/2026

CHARITE UNIVERSIT...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

CHARITE UNIVERSITAETSMEDIZIN BERLIN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-02-16

ERC-2020-COG: ERC CONSOLIDATOR GRANTS

I+D

Cerrada hace 4 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

CHARITE UNIVERSITAETSMEDIZI...

1.92M€ | Lider

SISTELEC SOLUCIONES DE TELEC...

431.40K€ | Participante

Universitätsklinikum Erlange...

76.70K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PREVENT RA Towards prevention of autoimmune diseases the case of rheum... 2M€ Cerrado

PID2021-128244OB-I00 REDES DE MICRORNAS REGULADORAS EN TOLERANCIA DE CELULAS B Y... 345K€ Cerrado

PREG-LAB Distinctive characterization of regulatory plasma cells and... 2M€ Cerrado

SAF2009-07100 FRECUENCIA, FENOTIPO Y FUNCION DE LAS CELULAS TH-17 EN LA AR... 157K€ Cerrado

Target to B-cure Targeting auto reactive B cells by vaccination to cure human... 3M€ Cerrado

CPP2021-008475 Valorización de una terapia antígeno-específica para el trat... 639K€ Cerrado

Duración del proyecto: 70 meses Fecha Inicio: 2021-02-16
Fecha Fin: 2026-12-31

Líder del proyecto

CHARITE UNIVERSITAETSMEDIZIN BERLIN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Rheumatoid Arthritis (RA) is a prototypic T cell- and B cell-driven inflammatory autoimmune disease that affects around 1% of the population worldwide and creates a severe burden for patients as well as substantial socioeconomic costs for society. Hallmarks of RA are a destructive inflammation of peripheral joints as well as the presence of autoantibodies such as anti-citrullinated protein antibodies (ACPA). Although ACPA are considered to represent major drivers of RA pathology, they can be also found in otherwise healthy individuals at risk where they emerge decades before the eventual onset of RA. Factors and mechanisms that promote onset of tissue inflammation in such autoantibody-positive individuals still remain elusive. Due to this gap of knowledge, current therapies are primarily designed to suppress later stages of joint inflammation, rather than targeting the underlying processes of autoimmunity or the initial onset of inflammatory disease. RA patients thus still lack effective preventive or curative therapeutic concepts. Here we aim to exploit recent technical breakthroughs such as single-cell RNA- and ATAC-sequencing in conjunction with DNA bar-coded MHC dextramers and antigens, spatial transcriptomics and cutting-edge imaging to perform a comprehensive and in-depth spatiotemporal analysis of the molecular events underlying the initial onset of inflammatory disease in autoantibody-positive individuals. We will additionally profit from the access to a large and well-characterized cohort of ACPA-positive individuals at risk and ACPA-positive RA patients as well as from corresponding biomaterial. In combination with preclinical animal models of RA, we thereby seek to delineate the sequences of events that promote the early transition from autoimmunity to inflammation. The obtained data will yield key insights into basic mechanisms of inflammatory autoimmune diseases such as RA and provide the basis for novel treatment concepts.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores